Lifecore Biomedical, Inc. announced in connection with the issuance of the Series A convertible preferred stock, Nathaniel Calloway, PhD and Christopher Kiper were appointed to the company's Board of Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | -2.18% | -2.67% | -5.82% |
19/04 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
01/04 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.82% | 18Cr | |
+37.74% | 72TCr | |
+34.31% | 59TCr | |
-2.07% | 37TCr | |
+20.25% | 33TCr | |
+2.99% | 28TCr | |
+17.06% | 24TCr | |
+9.73% | 21TCr | |
-4.17% | 21TCr | |
+2.81% | 17TCr |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Lifecore Biomedical, Inc. Announces Board Appointments